ReviewNature reviews. Disease primers2022
Hypothalamic syndrome.
Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Efficacy and Safety of Bariatric Surgery in Acquired Hypothalamic Obesity: A Systematic Review and Individual Patient Data Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Could setmelanotide be the game-changer for acquired hypothalamic obesity?Frontiers in endocrinology · 2023Trial
- Apc-deficient pituitary stem cells drive adamantinomatous craniopharyngioma through senescence-associated inflammation.EMBO molecular medicine · 2026Article
- IMPROVE 2025: The 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence.Clinical obesity · 2026Article
- Approach to the patient with acquired hypothalamic syndrome.The Journal of clinical endocrinology and metabolism · 2026Review
- Multidisciplinary Management of Pediatric Craniopharyngioma: From Diagnosis to Long-Term Outcomes.Biomedicines · 2026Review
- Sympathetic hyperactivation following endoscopic third ventriculostomy: a rare and underrecognized postoperative complication. Illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Reproduction under Siege: How Chronic Stress Hijacks the HPG Axis?Neuroendocrinology · 2026Review
- Postprandial Glucagon Action in the Human Brain.Diabetes, obesity & metabolism · 2026Article
- Current Approaches and Therapeutic Strategies for Hypothalamic Syndrome in Patients with Childhood-onset Craniopharyngioma.Journal of clinical research in pediatric endocrinology · 2026Review
- Understanding the burden of endocrine and metabolic disorders in Prader-Willi syndrome: data from the Italian registry.Journal of endocrinological investigation · 2026Article
- Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs.Neuro-oncology practice · 2026Article
- Development and validation of a predictive model for hypothalamic obesity following craniopharyngioma resection.BMC endocrine disorders · 2026Article
- Management of Childhood Obesity.International journal of molecular sciences · 2026Review
- Review
- Hyperphagia in craniopharyngioma- a real-world study from the international hypothalamic-pituitary brain tumors patient registry.Scientific reports · 2026Article
- Diagnostic criteria for acquired hypothalamic obesity - international expert guidance document.Endocrine journal · 2026Review
- Exploring the Role of Skull Base Anatomy in Surgical Approach Selection and Endocrinological Outcomes in Craniopharyngiomas.Journal of clinical medicine · 2026Article
- The association between reduced hypothalamic subregion volume and aortic aneurysm risk: a Mendelian randomization and multi-omics study with clinical MRI validation.Frontiers in cardiovascular medicine · 2026Article
- Case Report: Effect of setmelanotide treatment in a young patient with acquired hypothalamic obesity followingFrontiers in endocrinology · 2026Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 6 countries.
Funding
Abstract
Hypothalamic syndrome (HS) is a rare disorder caused by disease-related and/or treatment-related injury to the hypothalamus, most commonly associated with rare, non-cancerous parasellar masses, such as craniopharyngiomas, germ cell tumours, gliomas, cysts of Rathke's pouch and Langerhans cell histiocytosis, as well as with genetic neurodevelopmental syndromes, such as Prader-Willi syndrome and septo-optic dysplasia. HS is characterized by intractable weight gain associated with severe morbid obesity, multiple endocrine abnormalities and memory impairment, attention deficit and reduced impulse control as well as increased risk of cardiovascular and metabolic disorders. Currently, there is no cure for this condition but treatments for general obesity are often used in patients with HS, including surgery, medication and counselling. However, these are mostly ineffective and no medications that are specifically approved for the treatment of HS are available. Specific challenges in HS are because the syndrome represents an adverse effect of different diseases, and that diagnostic criteria, aetiology, pathogenesis and management of HS are not completely defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.